没有治疗的转移性乳腺癌患者的生存率:"如果我什么都不做呢?"
Jennifer K Plichta1,2,3, Samantha M Thomas4,5, Xuanji Wang6
1Department of Surgery, Duke University Medical Center, DUMC 3513, Durham, NC, 27710, USA. Jennifer.Plichta@duke.edu.
Breast cancer research and treatment
|March 4, 2024
概括
没有接受治疗的新发转移性乳腺癌 (dnMBC) 患者的生存结果令人丧. 未经治疗的患者往往有侵略性疾病,年龄较大和并发症,导致与治疗患者相比生存时间显著缩短.
科学领域:
- 在瘤学瘤学.
- 临床研究 临床研究
- 流行病学 流行病学
背景情况:
- 新发性转移性乳腺癌 (dnMBC) 是指在诊断时已经扩散的癌症.
- 没有接受任何治疗的dnMBC患者的治疗决策和生存结果没有得到很好的描述.
研究的目的:
- 评估被诊断为新发转移性乳腺癌 (dnMBC) 的没有接受任何治疗的患者的生存结果.
- 为了确定与未经治疗的dnMBC中存活相关的患者和疾病特征.
主要方法:
- 从国家癌症数据库 (2010-2016) 中对成人 dnMBC 患者的回顾性分析.
- 分层分为"接受治疗" (至少接受了一次治疗) 和"未接受治疗" (没有接受任何治疗) 组.
- 卡普兰-梅尔总生存率 (OS) 估计方法和因子关联的考克斯比例危险模型.
主要成果:
- 在53,240名dnMBC患者中,7.9%没有接受治疗. 没有接受治疗的患者年龄较大,并发病率较高,三阴性疾病较多,转移部位较多.
- 未接受治疗的患者的平均整体存活期 (OS) 为2.5个月,而接受治疗的患者为36.4个月 (p < 0.001).
- 在未接受治疗的患者中,更糟糕的OS与年龄较大,更高的并发症得分,更高的瘤等级和三阴性亚型有关.
结论:
- 没有接受治疗的dnMBC患者通常年龄较大,有并发症,并存在侵袭性疾病.
- 未经治疗的dnMBC中的存活率受到患者和疾病特征的影响,类似于接受治疗的人群.
- 未经治疗的新发转移性乳腺癌的预后仍然非常差.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
265
05:05Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy
Published on: November 29, 2018
10.7K
相关概念视频
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Kaplan-Meier Approach
137
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
137
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
